Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2026-07-10 20:00:05 ET · period of report 2026-07-08 · accession 0001864158-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-07-10 20:00 | 2026-07-08 | JANX | Campbell David Alan | Pres, CEO, Dir | M - OptEx | $4.21 | +7,000 | 388.6K | +2% | +$29.5K |
| D | 2026-07-10 20:00 | 2026-07-08 | JANX | Campbell David Alan | Pres, CEO, Dir | M - OptEx | $0.00 | -7,000 | 697.5K | -1.0% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-08 | M | A | 7,000 | $4.21 | 388,582 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2026-07-08 | M | D | 7,000 | $0.00 | 697,550 | D | $4.21 · — to 2031-03-09 | 7,000 Common Stock | (F1) Immediately exercisable. |